Prospect application of magneto-enzymatic sensitive liposome for imaging and targeted release in oral squamous cell carcinoma
The multimodal capabilities of nanoparticle delivery system offer the opportunity to develop novel approaches to deliver drugs that may result in alternative or complementary therapeutic options for the treatment of disease. Our research group has designed a magneto-enzymatic sensitive liposome (MESL) which is used for targeted optical imaging and local drug release. The liposome is formed by self-organization of amphiphilic sphingomyeline (SM), which can be hydrolyzed by acid sphingomyelinase (aSMase) and subsequent generate ceramide. MESL contains ICG for fluorescent labeling and cisplatin as a chemotherapeutic agent for treatment. Local enzymatically release will be triggered by aSMase, which is produced in cancer tissue or induced by cellular stress through radiation, hypoxia or chemical drugs. Iron particles in the lipid bilayer membrane of the liposome will amplify activation through alternating magnetic field (AMF) by harmless magnetic fields. These two activation mechanisms enable locally controlled release. The aim of this study was to evaluate the combined opening power of SMase and AMF, the efficiency of Indocyanine Green (ICG) for fluorescent labeling and cisplatin as a chemotherapeutic agent for treatment in vitro assay. The theoretical basis of MESL and possible applications of MESL nanoparticle carrier in vivo medicine was studied. Specific information as follows: Optical properties of environment sensing ICG-MESL probe; In vitro characterization: ASMase activity as a cell stress indicator through irradiation and cisplatin in head and neck squamous cell carcinoma (HNSCC) lines; In Vivo characterization: aSMase activity of HNSCC and muscle in mouse
Use and reproduction:
No license. The provisions of the German Copyright Act (UrhG) apply.
Please note that individual components of the publication may be subject to other licensing or copyright conditions.